Autologous Mitochondrial Transplant for Cerebral Ischemia

Launched by UNIVERSITY OF WASHINGTON · Aug 1, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for patients with cerebral ischemia, which occurs when blood flow to the brain is reduced, leading to potential brain damage. The researchers are looking to see if infusing healthy mitochondria—tiny energy-producing structures from each patient's own body—into the blood vessels that supply the affected part of the brain can improve recovery, especially for those who are already receiving standard treatments like endovascular thrombectomy (a procedure to remove blockages in the brain).

To be eligible for this trial, participants generally need to be between 65 and 74 years old and must be candidates for specific procedures used to treat large blood vessel blockages or complications from brain aneurysms. Patients who cannot safely undergo certain scans or have known mitochondrial diseases will not be included. If participants join the study, they can expect to receive the mitochondria infusion along with their usual care, and the team will closely monitor their progress. This trial is currently recruiting participants, and it's an exciting opportunity to explore a potential new way to support brain recovery after ischemia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Eligible for endovascular thrombectomy to treat acute large vessel occlusion
• • Eligible for angioplasty (microcatheter-based balloon/mechanical and chemical angioplasty) to treat acute cerebral vasospasm after aneurysmal subarachnoid hemorrhage
• • Subjects for whom there is likely to be enough time to obtain meaningful consent from patient or legally-authorized representative
• Exclusion Criteria:
• • Unable to receive a brain MRI scan
• • Known mitochondrial disease
• • Hemodynamically unstable patients in whom standard of care endovascular reperfusion treatment cannot safely be performed or completed